Abstract
Primary biliary cholangitis (PBC) is an autoimmune cholestatic liver disease diagnosed with elevated alkaline phosphatase in the presence of antimitochondrial antibody. With the introduction and widespread use of ursodeoxycholic acid the proportion of PBC patients undergoing liver transplant (LT) has decreased. However, up to 40% of patients are ursodeoxycholic acid nonresponders and require second-line treatment or progress to end-stage liver disease requiring LT. Several scoring systems have been developed and validated to assess treatment response and transplant-free survival in patients. Although PBC is a favorable indication for LT, recurrence of PBC may occur and requires biopsy for diagnosis.
Original language | English (US) |
---|---|
Pages (from-to) | 613-624 |
Number of pages | 12 |
Journal | Clinics in liver disease |
Volume | 22 |
Issue number | 3 |
DOIs | |
State | Published - Aug 2018 |
Keywords
- GLOBE score
- Liver transplant
- Mayo Risk Score
- Obeticholic acid
- Primary biliary cholangitis
- Recurrent PBC
- UK-PBC
- Ursodeoxycholic acid
ASJC Scopus subject areas
- Hepatology